

CASTA DIVA GROUP

BUY

Sector: Media Price: Eu1.22 - Target: Eu2.60Eu


Pharma and Major Events, Two Promising New Developments

Websim Research Dpt.: 39-02-76418200 research@websim.it

Stock Rating

Rating:		Unchanged				
Target Price (Eu):	:	fror	n 2.50 to 2.60			
	2024E	2025E	2026E			
Chg in Adj EPS	-2.2%	6.6%	2.9%			

CASTA DIVA GROUP - 12M Performance



Stock Data			
Reuters code:			CDG.MI
Bloomberg code:			CDG IM
Performance	1M	3M	12M
Absolute	-2.2%	-14.5%	-6.0%
Relative	-2.6%	-15.7%	-20.3%
12M (H/L)			1.73/1.06
3M Average Volun	ne (th):		35.31

Shareholder Data	
No. of Ord shares (mn):	20
Total no. of shares (mn):	20
Mkt Cap Ord (Eu mn):	24
Total Mkt Cap (Eu mn):	24
Mkt Float - Ord (Eu mn):	10
Mkt Float (in %):	41.2%
Main Shareholder:	
Reload s.r.l.	47.2%
Bulliana Charat Batta	

Balance Sheet Data	
Book Value (Eu mn):	16
BVPS (Eu):	0.79
P/BV:	1.5
Net Financial Position (Eu mn):	-12
Enterprise Value (Eu mn):	37

- First Class and Artificio Italiano join the Casta Diva family. Over the Christmas holidays, the Casta Diva group announced the closing of two extraordinary deals. The companies purchased were First Class, a prestigious agency with a consolidated twenty-year presence in the design and organisation of medicalscientific congresses, and Artificio Italiano, an established agency active in the creative design of major celebratory events in Italy and abroad. With aggregate turnover of c.€8.5mn and adjusted EBITDA of c.€0.8mn, the companies were purchased for a total of €3.27mn (for 100% of the capital in both cases), confirming the multiples recorded for similar transactions in the past.
- 2025-26 EBITDA revised upwards by 2% on average. The consolidation of First Class and Artificio Italiano has led us to revise 2025-26 adjusted EBITDA cautiously upwards, by 2% on average, with a corresponding increase of 5% on average in adjusted EPS. We highlight how the estimate revision (i) does not include potential synergies deriving from the inclusion of the newly-acquired companies within the group and (ii) features a slight trim to Casta Diva's standalone organic growth potential, exclusively due to a more conservative macroeconomic outlook. Conversely, our 2024 estimates are basically unchanged at adjusted level.
- BUY confirmed, target price raised to €2.60 (from €2.50 previously). We reiterate our positive view on the stock after the announcement of the acquisitions of First Class and Artificio Italiano, which we believe can offer new and promising areas for the Casta Diva group to develop. First Class allows Casta Diva to gain a leading role in a market segment in which it only recently gained a foothold (through the creation of a dedicated division under Alessandro Scattolin), as it will be able to draw on the acquired company's consolidated relationships and a management team with significant sector expertise, while Artificio Italiano can be the key to the large celebratory events segment, combining the new company's offer with the Casta Diva group's established implementation and logistical capabilities. We reiterate our BUY recommendation, raising our target price to €2.60 per share due to the upward revision to estimates.

Key Figures & Ratios	2022A	2023A	2024E	2025E	2026E
Sales (Eu mn)	84	111	118	137	151
EBITDA Adj (Eu mn)	7	10	12	15	17
Net Profit Adj (Eu mn)	2	3	4	6	7
EPS New Adj (Eu)	0.115	0.130	0.219	0.302	0.362
EPS Old Adj (Eu)	0.115	0.130	0.224	0.283	0.351
DPS (Eu)	0.000	0.080	0.043	0.060	0.071
EV/EBITDA Adj	1.8	3.1	3.9	2.5	1.9
EV/EBIT Adj	2.7	4.5	5.6	3.5	2.5
P/E Adj	10.6	9.4	5.6	4.1	3.4
Div. Yield	0.0%	6.6%	3.5%	4.9%	5.8%
Net Debt/EBITDA Adj	0.0	0.9	1.5	0.8	0.4

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein, and any of its parts, is strictly prohibited. None of the contents of this document may be shared with third parties without Company authorization. Please see important disclaimer on the last page of this report

" websim

CASTA DIVA GROUP – Key Figures	20244	20224	20224	20245	20255	2026-
Profit & Loss (Eu mn)	2021A	2022A	2023A	2024E	2025E	2026E
Sales	27	84	111	118	137	151
EBITDA	1	6	9	10	14	17
EBIT	0	4	5	6	10	12
Financial Income (charges)	-0 0	-0 0	-1 0	-1 0	-1 0	-0 0
Associates & Others Pre-tax Profit	0	3	4	5	10	12
Taxes	0	-2	-3	-2	-4	-5
Tax rate	-33.2%	46.3%	-5 56.8%	40.0%	40.0%	40.0%
Minorities & Discontinued Operations	-0	0	0	40.0%	0	40.0%
Net Profit	0	2	2	3	6	7
EBITDA Adj	1	7	10	12	15	17
EBIT Adj	1	5	7	8	11	12
Net Profit Adj	1	2	3	4	6	7
Per Share Data (Eu)	2021A	2022A	2023A	2024E	2025E	2026E
· , ,	19	2022A 20	2023A	2024E	2023E	20286
Total Shares Outstanding (mn) - Average Total Shares Outstanding (mn) - Year End	19	20	20	20	20	20
EPS f.d	0.023	0.079	0.082	0.157	0.283	0.357
EPS Adj f.d	0.023	0.115	0.130	0.137	0.302	0.362
BVPS f.d	0.328	0.406	0.433	0.554	0.794	1.091
Dividend per Share ORD	0.328	0.406	0.433	0.554	0.794	0.071
Dividend per Share SAV	0.000	0.000	0.000	0.000	0.000	0.000
Dividend Payout Ratio (%)	0.0%	0.0%	76.5%	20.0%	20.0%	20.0%
Cash Flow (Eu mn)	2021A	2022A	2023A	2024E	20.0% 2025E	20.0% 2026E
Gross Cash Flow	2021A 1	2022A	2023A 5	7	10	11
Change in NWC	-0	8	-4	-2	-1	-1
Capital Expenditure	-0 -1	-6	-11	-13	-3	-1 -4
Other Cash Items	0	-0 -1	0	-0	-3 -0	-4 -0
Free Cash Flow (FCF)	-0	5	-9	-8	6	-u 7
Acquisitions, Divestments & Other Items	0	0	0	0	0	0
Dividends	0	0	-1	-1	-1	-1
Equity Financing/Buy-back	0	0	-0	0	0	0
Change in Net Financial Position	0	4	-10	-8	5	6
Balance Sheet (Eu mn)	2021A	2022A	2023A	2024E	2025E	2026E
Total Fixed Assets	10	13	2023A	20241	23	20201
Net Working Capital	2	-4	-1	6	7	9
Long term Liabilities	-1	-2	-2	-2	-2	-2
Net Capital Employed	11	8	18	29	29	28
Net Cash (Debt)	-4	0	-9	-18	-12	-6
Group Equity	7	9	9	11	16	22
Minorities	1	1	0	0	0	0
Net Equity	6	8	9	11	16	22
Enterprise Value (Eu mn)	2021A	2022A	2023A	2024E	2025E	2026E
Average Mkt Cap	7	10	22	28	24	24
Adjustments (Associate & Minorities)	-2	-2	-1	-1	-1	-0
Net Cash (Debt)	-4	0	-9	-18	-12	-6
Enterprise Value	14	12	32	47	37	31
Ratios (%)	2021A	2022A	2023A	2024E	2025E	2026E
EBITDA Adj Margin	5.5%	8.4%	9.2%	10.1%	10.7%	11.1%
EBIT Adj Margin	2.9%	5.5%	6.3%	7.0%	7.8%	8.3%
Gearing - Debt/Equity	59.1%	-3.1%	103.1%	152.7%	75.0%	27.7%
Interest Cover on EBIT	2.9	7.9	5.4	6.4	15.3	32.7
Net Debt/EBITDA Adj	2.7	0.0	0.9	1.5	0.8	0.4
ROACE*	4.7%	41.1%	40.7%	26.6%	35.6%	43.8%
ROE*	14.1%	31.8%	31.6%	44.4%	44.7%	38.4%
EV/CE	1.3	1.3	2.4	2.0	1.3	1.1
EV/Sales	0.5	0.1	0.3	0.4	0.3	0.2
EV/EBITDA Adj	9.1	1.8	3.1	3.9	2.5	1.9
EV/EBIT Adj	17.5	2.7	4.5	5.6	3.5	2.5
Free Cash Flow Yield	-0.2%	20.4%	-36.9%	-31.1%	25.0%	29.6%
Growth Rates (%)	2021A	2022A	2023A	2024E	2025E	2026E
Sales	72.4%	209.8%	32.6%	6.6%	16.2%	9.9%
EBITDA Adj	nm	373.0%	45.4%	17.4%	23.4%	13.5%
EBIT Adj	nm	494.7%	52.4%	18.4%	29.4%	16.0%
Net Profit Adj	nm	174.7%	17.6%	69.4%	37.6%	19.9%
				60.00/	27.60/	40.00/
EPS Adj	nm	168.3%	12.4%	69.0%	37.6%	19.9%

 $[\]hbox{*Excluding Extraordinary Items Source: Websim Corporate estimates}$





With First Class, Casta Diva can (also) take centre stage in the medical-scientific congress sector.

Following the initial announcement in September last year, on 27 December Casta Diva announced the purchase of 100% of the capital of First Class S.r.l., one of the most prestigious Italian events agencies in the field of medical congresses, which over the years has secured preferential relationships with key Italian and international opinion leaders.

Founded in 2005 by Laura Bernardini, First Class conceives and organises events and conferences all around the world, mainly in the medical-scientific field for large pharmaceutical companies with significant skills in radiology, neurological diseases and many other therapeutic areas.

First Class is also a Ministry of Health-accredited CME¹ provider, approved for the provision of residential training and distance learning throughout Italy and Europe.

Its creative, technical, compliance and logistical expertise enabled First Class to close FY23 with a production value of €7.5mn and a near-double-digit adjusted EBITDA margin (i.e. €740,000, or 9.9% of the value of production).

The agreement values 100% of the company's capital at €3.18mn, based on its economic and financial performance over the last two fiscal years. The sum will be paid in two instalments: the first 65% chunk was paid at closing, while the balance will be paid after 18 months, i.e. in June 2026.

As part of the agreement: (i) the founder of First Class, Laura Bernardini, has signed a 12-month management agreement (which can be extended) and a non-compete agreement for a further two years, and (ii) the selling party has granted representations and warranties, as is the practice in this type of transaction.

Casta Diva's newly-established Pharma division is therefore starting to take shape, fulfilling its ambition to enter the medical-scientific events market with a leading role thanks to an agency of high standing with a dedicated management team of proven experience, led by Alessandro Scattolin.

KITONB

Major events and ceremonies the Artificio Italiano trump card.

On 19 December, the Casta Diva group announced the acquisition of 100% of the capital of Artificio Italiano through its subsidiary G2 Eventi. Artificio Italiano is a creative agency specialising in major celebratory events in Italy and abroad. It also manages the Kitonb creative studio, operational since 1998.

The acquired company, which will be renamed Casta Diva Art & Show, boasts significant expertise in major celebratory events thanks to a success story that has seen its shows and performances open major events around the world.

This deal, which builds on a fruitful partnership between the two companies, values 100% of Artificio Italiano's economic capital at €90,000, paid in a single instalment at closing.²

Although Artificio Italiano's 2024 turnover was limited (c.€1mn), its future integration into Casta Diva's broader scope, both corporate and in terms of the range of skills, should give turnover a significant boost in a very rich and prestigious market, thanks to the integration of production and logistics activities.

Artificio Italiano: Brescia City of Culture (2023) by Kitonb Projects





Source: Kitonb Projects, company website

¹CME: Continuing Medical Education, i.e. the process by which the health professional keeps up to date, in compliance with the continuous training obligations to which health professionals are legally subject

²Light is Life in Bergamo, Brescia City of Culture 2023, award of the Closing Ceremony of the Milan-Cortina Paralympics 2026



Casta Diva: 2024-2026 Consolidated Estimates Revision

(Eu mn)	2024 New	2025 New	2026 New	2024 Old	2025 Old	2026 Old	Δ FY24 (%)	Δ FY25 (%)	Δ FY26 (%)
Net Sales	118.2	137.3	151.0	118.2	131.5	146.1	0.0%	4.4%	3.4%
% YoY growth	6.6%	16.2%	9.9%	6.6%	11.3%	11.1%			
Other revenues	1.4	1.4	1.5	1.4	1.4	1.5			
Value of Production	119.6	138.8	152.5	119.6	132.9	147.6	0.0%	4.4%	3.3%
Operating expenses	(107.6)	(124.0)	(135.8)	(107.7)	(118.5)	(131.1)			
Adjusted EBITDA	11.9	14.7	16.7	11.9	14.4	16.5	0.3%	2.3%	1.3%
% of net sales	10.1%	10.7%	11.1%	10.1%	10.9%	11.3%			
Non-recurring items	(2.0)	(0.5)	0.0	(1.5)	(0.5)	0.0			
Reported EBITDA	9.9	14.2	16.7	10.4	13.9	16.5	-4.5%	2.3%	1.3%
% of net sales	8.4%	10.4%	11.1%	8.8%	10.6%	11.3%			
% YoY growth	16.0%	43.1%	17.5%	21.8%	33.0%	18.9%			
D&A and Provisions	(3.6)	(4.0)	(4.2)	(3.6)	(4.3)	(4.4)			
Reported EBIT	6.3	10.2	12.5	6.8	9.6	12.1	-7.3%	6.7%	3.0%
% of net sales	5.3%	7.5%	8.3%	5.8%	7.3%	8.3%			
% YoY growth	16.5%	62.5%	21.6%	25.7%	40.6%	26.1%			
Net Financial Charges	(1.0)	(0.7)	(0.4)	(0.8)	(0.6)	(0.4)			
Associates	0.0	0.0	0.0	0.0	0.0	0.0			
Pre-tax Profit	5.3	9.6	12.1	6.0	8.9	11.7	-11.3%	7.6%	3.2%
Taxes	(2.1)	(3.8)	(4.8)	(2.4)	(3.6)	(4.7)			
tax rate	40%	40%	40%	40%	40%	40%			
Consolidated Net Profit	3.2	5.7	7.2	3.6	5.4	7.0	-11.3%	6.4%	3.5%
% of net sales	2.7%	4.2%	4.8%	3.0%	3.8%	4.5%			
Net Financial Position	(17.5)	(12.2)	(6.2)	(15.0)	(9.6)	(2.2)			

Source: Websim Corporate estimates

DETAILS ON STOCKS RECOMMENDATION				
Stock NAME	CASTA DIVA GROUP			
Current Recomm:	BUY	Previous Recomm:	BUY	
Current Target (Eu):	2.60	Previous Target (Eu):	2.50	
Current Price (Eu):	1.22	Previous Price (Eu):	1.25	
Date of report:	15/01/2025	Date of last report:	01/10/2024	



DISCLAIMER (for more details go to DISCLAIMER)

IMPORTANT DISCLOSURES

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein and of any its parts is strictly prohibited. None of the contents of this document may be shared without authorisation from Intermonte.

This report is directed exclusively at market professional and other institutional investors (Institutions) and is not for distribution to person other than "Institution" ("Non-Institution"), who should not rely on this material. Moreover, any

This report is oracle exclusively at manker processional and other institutional institutions. Institution in the property of the institution in the property of the institution in the property of the institution. The information and data in this report have been obtained from sources which we believe to be reliable, although the accuracy of these cannot be guaranteed by Intermonte. In the event that there be any doubt as to their reliability, this will be clearly indicated. The main purpose of the report is to offer up-to-date and accurate information in accordance with regulations in force covering "recommendations" and is not intended nor should it be construed as a solicitation to buy or sell securities.

absolution to duy of set according. question. For a list of all recommendations made by Intermonte on any financial instrument or issuer in the last twelve months consult the PERFORMANCE web page.

Intermonte distributes research and engages in other approved activities with respect to Major U.S. Institutional Investors ("Majors") and other Qualified Institutional Buyers ("QIBs"), in the United States, via Plural Securities LLC under SEC 15a-6 guidelines. Intermonte is not registered as a broker dealer in the United States under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is not a member of the Securities Investor Protection Corporation ("SIPC"). Plural Securities LLC is registered as a broker-dealer under the Exchange Act and is a member of SIPC.

ANALYST CERTIFICATION

ANALYSI CERLIFICATION

For each company mentioned in this report the respective research analyst hereby certifies that all of the views expressed in this research report accurately reflect the analyst's personal views about any or all of the subject issuer (s) or securities. The analyst (s) also certify that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation or view in this report.

The analyst (s) responsible for preparing this research report receive(s) compensation that is based upon various factors, including Intermonte's total profits, a portion of which is generated by Intermonte's corporate finance activities, although this is minimal in comparison to that generated by brokerage activities.

Intermonte's internal procedures and codes of conduct are aimed to ensure the impartiality of its financial analysts. The exchange of information between the Corporate Finance sector and the Research Department is prohibited, as is the exchange of information between the latter and the proprietary equity desk in order to prevent conflicts of interest when recommendations are made.

The analyst responsible for the report is not a) a resident of US; b) an associated person of a U.S. broker-dealer; c) supervised by a supervisory principal of a U.S. broker-dealer. This Research Report is distributed in the U.S. through Plural Securities LLC, 950 3rd Ave, Suite 1702, NY 10022, USA.

GUIDE TO FUNDAMENTAL RESEARCH

The main methods used to evaluate financial instruments and set a target price for 12 months after the investment recommendation are as follows:

Discounted cash flow (DCF) model or similar methods such as a dividend discount model (DDM)

- Comparison with market peers, using the most appropriate methods for the individual company analysed: among the main ratios used for industrial sectors are price/ earnings (P/E), EV/EBITDA, EV/EBITD, EV/EBITDA, EV/EBITDA value are used

 For the utilities sector comparisons are made between expected returns and the return on the regulatory asset base (RAB)

Some of the parameters used in evaluations, such as the risk-free rate and risk premium, are the same for all companies covered, and are updated to reflect market conditions. Currently a risk-free rate of 4.0% and a risk premium of 5.5% are being used.

Frequency of research: quarterly

Reports on all companies listed on the S&PMIB40 Index, most of those on the MIDEX Index and the main small caps (regular coverage) are published at least once per quarter to comment on results and important newsflow.

A draft copy of each report may be sent to the subject company for its information (without target price and/or recommendations), but unless expressly stated in the text of the report, no changes are made before it is published Explanation of our ratings system:

BUY: stock expected to outperform the market by over 25% over a 12 month period;

DUTPERFORM: stock expected to outperform the market by over 23% over a 12 minutin period;

NEUTRAL: stock performance expected at between +10% and -10% compared to the market over a 12 month period;

NEUTRAL: stock performance expected at between +10% and -10% compared to the market over a 12 month period;

UNDERPERFORM: stock expected to underperform the market by between -10% and -25% over a 12 month period;

SELI: stock expected to underperform the market by over 25% over a 12 month period.

Prices: The prices reported in the research refer to the price at the close of the previous day of trading

CURRENT INVESTMENT RESEARCH RATING DISTRIBUTIONS

Intermonte SIM is authorised by CONSOB to provide investment services and is listed at n° 246 in the register of brokerage firms.

As at 31 December 2024 Intermonte's Research Department covered 132 companies. Intermonte's distribution of stock ratings is as follows:

BUY:	31.34 %
OUTPERFORM:	43.28 %
NEUTRAL:	25.38 %
UNDERPERFORM	00.00 %
SELL:	00.00 %

The distribution of stock ratings for companies which have received corporate finance services from Intermonte in the last 12 months (71 in total) is as follows:

BUY:	50.70 %
OUTPERFORM:	29.58 %
NEUTRAL:	19.72 %
UNDERPERFORM	00.00 %
SELL:	00.00 %

In order to disclose its possible conflicts of interest Intermonte SIM states that:

Intermonte is acting as financial advisor to Retex S.p.A. – Società Benefit in relation to the voluntary public tender offer launched on Alkemy S.p.A

Intermonte SIM has provided in the last 12 months / provides / may provide investment banking services to the following companies: Aquafil, Banca Ifis, Civitanavi Systems, Cy4Gate, Esprinet, GPI, Eagle (on Greenthesis shares), Growens, Illimity Bank, Maire

Tecnimont, SAES Getters, Tinesta, Unidata and WillT.

Intermonte SIM is acting as counterparty to Will Tin S.r.I. in connection with call and put options having Will S.p.A. shares and dividends as reference underlying.

Intermonte SIM is specialist and/or Corporate Broker and/or Sporasor and/or Broker in charge of the share buy back activity of the following Companies: Abitare In, Alkermy, Anima Holding, Antares Vision, Aquafil, Avio, Banca Ifis, Banca Sistema, Civitan Systems, Cyberoo, Cy4gate, DHH, El.En, Elica, Emak, Esprinet, Firnit - Fondo Alpha, Fine Foods, Franchi Umberto Marmi, GPI, Greenthesis (formerly Ambienthesis), IEG, IndelB, Intred, Luve, Misitano & Stracuzzi, Mondadori, Notorious Pictures, Omer, Pharmanu

Agreed to the poly, Revo Insurance, Reway, Sees Cetters, Sciuker Frames, Servizi Italia, Seas, Ser Industrial, Somec, Star?, Sy-Dat Group, Talea, Tambur, Tinesta, Tesmec, The Italian Sea Group, TXT, Unidata, Webuild and WIIT.

Intermonte SIM has a contractual commitment to act as liquidity provider on behalf of third parties for the following company: Banca Sistema.

Intermonte SIM performes as a market maker for the following companies: AZA, Anima, Atlantia, Autogrill, Azimut Holding, BAMI, Banca Generali, Banca Mediolanum, Brembo, Buzzi, CNHI, Enel, ENI, Exor, Fineco, FCA, FTMIB, Generali, Italgas, Iren, Intesa Sanpaolo, Leonardo, Mediobanca, Moncler, Mediaset, PierliBic, Crysmian, Poste, Ferrari, Sajpem, Snam, STM, Fearsi, Felecom Italia, See, Terna, UBI, Unicredit, Unipol, Un Milano, Fope, FOS, Franchi Umberto Marmi, Giglio Group, GM Leather, GPI, Green Oleo, High Quality Food, Ikonisys, Intercos, Intred., ISCC Fintech, Lemon Sistemi, Lventure Group, Mare Group, Mare Group, Mas Agricola, Matica Fintec, Mistano & Stracuzzi, Neodecortech, Notorious Pictures, Oildata, Osai Automation System, Racing Force Group, Redfish Long Term Capital, Relatech, Reti, Sciuker Frames, SG Company, Solid World Group, Spindox Digital Soul, Talea, Tamburi, Tesmec, Tinexta, TMP Group, Troedwice, Ulisse Biomed, Xenia Holtelenie Solution Spa Società Benefit, Wilt, Zest. Intermonte SIM SpA holds net long or short positions in excess of 0.5% of the overall share capital in the following issuers:

Emittente	%	Long/Short	
-----------	---	------------	--

© Copyright 2025 by Intermonte SIM - All rights reserved

It is a violation of national and international copyright laws to reproduce all or part of this publication by email, xerography, facsimile or any other means. The Copyright laws impose heavy liability for such infringement. The Reports of It is a violation on automation and international copyright laws to reproduce air of part of this publication by email, setting any internation and international and international management. Inexports of intermonte SIM are provided to its clients only. If you are not a client of Intermonte SIM and receive emailed, faxed or copied versions of the reports from a source other than intermonte SIM you are violating the Copyright Laws. This document is not for attribution in any publication, and you should not disseminate, distribute or copy this e-mail without the explicit written consent of Intermonte SIM.

INTERMONTE will take legal action against anybody transmitting/publishing its Research products without its express authorization.

INTERMONTE Sim strongly believes its research product on Italian equities is a value added product and desquately paid.

Intermonte Sim sales representatives can be contacted to discuss terms and conditions to be supplied the INTERMONTE research product.

INTERMONTE SIM is MIFID compliant - for our Best Execution Policy please check our Website MIFID